[HIGHLIGHTS] AI accelerates drug discovery, but its prospects still need to be tested in practice

AI-designed drugs have entered the early stages of clinical trials in the past few years. Salve Therapeutics is combining machine learning with computer-aided design to develop antibiotics in the form of bacteriophages.

NVIDIA has developed BioNeMo, a cloud service for generative AI in biology that provides a variety of AI models for small molecules and proteins. Some AI-developed protein variants are more effective than their natural forms, according to a report by the British "Nature" website.